Respecting the actual HER2+ BC therapeutic setting, the most recent studies try to improve the results of patients adding new anti-HER2 drugs, still without a selection by molecular features, thus, achieving a discrete therapeutic benefit in the most of these trials, and increasing toxicity and costs. This evidence concerns the gene ERBB2 and breast cancer.